Menu Close

Category: Daily News

San Rafael Pharmacy Resolves DEA Dispute

United States Attorney Brian J. Stretch and Drug Enforcement Administration (DEA) Special Agent in Charge John J. Martin announced that Golden Gate Pharmacy Holdings and its wholly owned subsidiaries, Golden Gate Pharmacy Services (GGPS) and Ross Valley Compounding Pharmacy (Ross Valley), have agreed to pay $717,250 to settle allegations by the U.S. Department of Justice that the companies failed to keep and maintain adequate records pertaining to controlled substances at their San Rafael, California facility.

Golden Gate Pharmacy Services and its sister pharmacy, Ross Valley Pharmacy have been providing traditional and nontraditional pharmacy services to Bay Area residents and Long Term Care Facilities since 1969. They have a physical location at 1525 Francisco Blvd East Suite #2 in San Rafael.

The settlement agreement, signed by Justice Department officials, was reached to resolve allegations by the government that a September 2014 DEA inspection uncovered multiple violations by GGPS and Ross Valley of the Controlled Substances Act, 21 U.S.C. § 801.

According to the agreement, San Rafael-based companies GGPS and Ross Valley each was, at the relevant time, registered with the DEA as a Retail Pharmacy providing them with authorizations to handle Schedules II, III, IIIN, and IV controlled substances.

GGPS and Ross Valley both acknowledged they had an obligation to “keep and maintain” records related to its receipt, manufacturing and distribution of controlled substances in connection with operations at their San Rafael, California facility.

According to the agreement, following the DEA’s inspection, the government concluded that between September 4, 2012, and September 4, 2014, GGPS and Ross Valley failed to record or maintain adequate inventory records or “records of the receipt, storage or shipment of controlled substances in at least 5,161 instances.”

In addition, according to the agreement, an employee at the San Rafael facility pilfered approximately 8,000 oxycodone tablets.

According to the terms of the agreement, Golden Gate Pharmacy Holdings, GGPS, and Ross Valley Pharmacy will pay the government $717,250 to resolve all civil claims related to the recordkeeping violations identified in the investigation.

Assistant U.S. Attorney Jonathan U. Lee handled this matter with the assistance of Garland He and Jessica Hurtado.

Is There Subrogation Potential in Kimberly-Clark Class Action?

It is likely that California employers have had many workers’ compensation claims filed over the years by health care workers who claim infectious injury. Some of these workers may have been wearing safety equipment sold by Kimberly-Clark Corporation and Halyard Health Inc. Claim department data mining and data analytics may identify these past and present claims.That discovery may lead to subrogation or a setoff petition should the claimants also be plaintiffs in the Los Angeles Class action filed against these companies.

A Los Angeles jury on Friday night hit Kimberly-Clark Corporation and Halyard Health Inc. with a stunning $454 Million fraud verdict due to the sale by the companies of defective medical devices to doctors, hospitals and trauma centers throughout California for years.

The unanimous verdict, rendered by an eight-person Federal Court jury after hearing extensive evidence in the two-week trial, is likely one of the largest verdicts in U.S. history against a medical device maker. Pursuant to an indemnification agreement entered into between the two defendants, Halyard Health is obligated to pay the entirety of the $454 Million awarded by the jury.

The class action lawsuit, Bahamas Surgery Center, LLC v. Kimberly-Clark Corp et al, Case No. CV 14-8390-DMG, was filed in Los Angeles in United States District Court in October 2014, alleging that the defendants had committed fraud in the marketing and sale of certain of their medical gowns used in critical surgeries.

In particular, the suit claimed that the companies had falsely represented to the FDA, health care workers and the general public that the company’s “Microcool Breathable High Performance Surgical Gowns” (the “Surgical Gowns”) were impermeable and provided protection against serious diseases, including Ebola and HIV, despite the fact that the companies had known since 2012 that the gowns were defective, failed industry tests, and did not meet relevant standards, thus placing healthcare professionals and patients at considerable risk for infection, serious bodily harm and death.

The jury sided with the Plaintiffs Friday and found that the companies had concealed material information from healthcare professionals throughout California and had carried out their scheme with malice, oppression and/or fraud. “This fraud verdict should send a clear message to corporations throughout the United States that concealment and cover-up are not part of doing business,” said lead attorney Michael Avenatti of Eagan Avenatti, LLP, on behalf of the Plaintiffs.

The evidence presented at trial showed that Kimberly-Clark and Halyard knowingly misled the medical community, regulators and the general public about the safety of the Surgical Gowns and even after learning of multiple test failures, failed to alert the FDA, healthcare professionals and patients. Internal e-mails and documents from the companies showed employees describing the manufacturing process as “crap” and admitting that they were knowingly using defective and substandard equipment to make the gowns in Honduras.

Instead of recalling the gowns and disclosing the truth, the companies concealed what they knew, fired employees who knew too much and continued promoting, marketing and selling the gowns by stating they were impermeable, even going so far as to recommend that the gowns be used when treating patients with serious infectious diseases, including Ebola and HIV.

The Plaintiffs were represented at trial by Michael Avenatti, Ahmed Ibrahim and Filippo Marchino of California-based Eagan Avenatti, LLP, together with William C. Hearon of William C. Hearon, PA, based in Miami, Florida.

DWC Spikes the Ball After WCIRB Announcement

Last week The WCIRB proposed a July 1, 2017 average advisory pure premium rate of $2.02 per $100 of payroll which is 16.5% lower than the corresponding industry average filed pure premium rate of $2.42 as of January 1, 2017 and 7.8% less than the Insurance Commissioner’s approved average January 1, 2017 advisory pure premium rate of $2.19.

The recent rate decline is therefore favorable to employers:

And following this announcement, Department of Industrial Relations Director Christine Baker made the following statement on the Workers’ Compensation Insurance Ratings Bureau’s recommendation for a mid-year 7.8 percent rate reduction:

“The 2012 reforms in SB 863 sought to increase benefits and improve care to injured workers while controlling rising costs for employers. Not only did benefits for injured workers increase by 30 percent, but an anticipated rate spike was prevented. Employers have had four consecutive rate reductions, and today’s recommendation will continue that trend”.

“Since 2012, DIR has made significant strides in its quest to eliminate medical provider fraud and illegitimate liens, and is continuing its efforts to launch a prescription drug formulary. These reform efforts seek to further improve treatment of injured workers while reducing costs in the system that would have been paid by employers. As evidenced by the WCIRB’s recommendation for a mid-year rate reduction, our recent reforms have brought both stability and sustainability to California’s workers’ compensation system.”

However, staying within the sports metaphor, the industry must also keep in mind the slogan “yesterday’s hits do not win today’s ball game.”

The Pennsylvania state Insurance Department approved a reduction in the annual workers’ compensation insurance premium rate, which the governor said will save employers $150 million. Benefits for injured workers will not be affected.

The Montana State Fund board of directors has reduced workers’ compensation rates by 5 percent, state officials said Wednesday, adding it was the 11th year in row that rates have remained the same or decreased.

The Ohio Bureau of Workers’ Compensation (BWC) has proposed a $1 billion rebate for Ohio’s private and public employers, the third such rebate since 2013.

The Maine Bureau of Insurance has approved a 4.3 percent decrease in the workers’ compensation insurance “loss cost” rate, which is expected to save Maine employers a combined $9.5 million over the next 12 months.

These are just recent examples of rate reductions occurring across the nation.  SB 899 was of course a good start for California.  It may not be the last successful play that is needed.

Lawyers Troll Carriers for MSP Recoveries – Who’s Next?

Miami lawyers expect a recent state court victory to pave the way for billions of dollars from liability and workers’ compensation insurance carriers across the nation to flow back to Medicare and its beneficiaries.

The attorneys, John Ruiz and Frank Quesada of the firm MSP Recovery, are going after major liability insurers for allegedly shirking their duty to reimburse Medicare benefit providers for conditional payments. Under the Medicare Secondary Payer law known by the acronym MCP, the government can recover double damages from a primary payer that fails to pay Medicare back for medical expenses covered by a liability policy

The home page of the firm boasts of the slogan aimed to attracted its clients who are Medicare Advantage insurance companies, challenging them to “DISCOVER YOUR LOSSES – RECOVER WHAT’S YOURS.”

According to the report in Daily Business Review, “Between 8 to 10 percent of all claims that are made through Medicare or Medicare Advantage Organizations are the responsibility of another payer,” Ruiz said – think car crashes, slip-and-fall accidents and workers’ compensation claims. “That’s a substantial amount because Medicare is paying in the vicinity of $600 billion a year.”

No attorney had ever secured class certification under the Medicare Secondary Payer law. A nuanced interplay between federal and state laws made it difficult to establish common issues of law and fact.

But MSP Recovery overcame those obstacles in Miami-Dade Circuit Court, where Judge Samantha Ruiz Cohen certified a class in a lawsuit against the auto insurer Ocean Harbor Casualty Insurance, a primary payer for thousands of Medicare Part C beneficiaries. In a 101-page decision, the judge ruled Medicare Advantage Organizations and others who contract with the government to provide Medicare benefits could sue Ocean Harbor as a class following an August federal appellate court decision.

That Eleventh Circuit decision, which arose from the Southern District of Florida case Humana v. Western Heritage, established that secondary payers could recover from a liability insurer if the case met three conditions: the defendant was a primary payer, the defendant failed to provide for primary payment or appropriate reimbursement, and the damages amount was established.

In state court, Ruiz Cohen ruled Ocean Harbor could not challenge the damages amounts because there was no evidence the auto insurer administratively contested any amounts paid, and the time for any administrative appeal had expired. Because of that failure to contest the reimbursement claims, all primary payer disputes arise under the Medicare Act, she ruled.

“Each class member will have incurred the same type of injury proximately caused by the same defendant based on the same general factual scenario, a failure to pay or reimburse as a primary payer for medical bills that resulted from an automobile accident during the claims period,” she wrote in the February order.

The judge also noted MSP Recovery has developed a sophisticated system to identify claims by collecting and matching data including Centers for Medicare & Medicaid Services reports, automobile crash reports, ambulance records, insurance declaration sheets and no-fault personal injury protection payout sheets.

The national penchant for claim “analytics” used to search for fraudulent claims may be a sword that swings both ways. “We’re able to figure out if someone that has had an incident – a car accident, a slip-and-fall – if another insurance carrier has reported to the government that they have a primary payer responsibility,” said Ruiz, also known for his variety of business enterprises, such as La Ley Sports.

That system has allowed the 30-attorney firm with roughly three dozen partner firms across the country to divide claims into categories and file lawsuits across the country on behalf of more than 100 health plans. Their firms boasts of about 17 class actions pending in state and federal courts across the nation.  Targeted defendants include companies such as Allstate Property & Casualty, Liberty Mutual, State Farm Mutual Automobile, Geico and others.

The class certification ruling is on appeal. Ocean Harbor attorney Shannon McKenna of Conroy Simberg in Hollywood said the company does not comment on pending litigation.

Ruiz and Quesada believe their cases will not only recover billions of dollars but will push primary payers to follow the law. The attorneys have already seen liability insurers change their payment practices because of the litigation.

“Before, it was almost like, ‘Catch me if you can,'” Ruiz said. “Now that we caught them, they are doing things differently.”

Cigna Reduces Opioid Use 12%

Since announcing its commitment to combat the nation’s opioid epidemic last year, Cigna has made significant progress toward reaching its goal to reduce opioid use among its customers with the help of health care providers. Within the last 12 months, Cigna customers’ use of prescribed opioids has declined nearly 12 percent – about halfway to achieving the company’s goal of 25 percent reduction by 2019.

While Cigna has adopted a multi-pronged response to the epidemic that includes multiple stakeholder groups, the key to this initial progress has been Cigna’s work with doctors, especially those that participate in its Cigna Collaborative Care arrangements.

To date, 158 medical groups participating in Cigna Collaborative Care, representing nearly 62,000 doctors, have signed Cigna’s pledge to reduce opioid prescribing and to treat opioid use disorder as a chronic condition.

“The opioid epidemic is far too big for any one person or organization to fight alone. Success will require the efforts of multiple stakeholders,” said Cigna President and CEO David Cordani. “e commend those who have joined the battle with us. Our collective steps are making a notable difference in the lives of our customers and their families. The decline in opioid use that we have seen in just one year is encouraging and reinforces how much more we can accomplish as we continue to work together.”

Cigna assists doctors in preventing, recognizing and treating opioid misuse by:

– – Analyzing integrated claims data across pharmacy and medical benefits to detect opioid use patterns that suggest possible misuse by individuals, and then notifying their health care providers. This helps identify individuals with substance use disorders more quickly so they can get the help they need.
– – Alerting doctors when their opioid prescribing patterns are not consistent with the Centers for Disease Control and Prevention’s (CDC) guidelines that include opioid selection, dosage, and duration.
– – Establishing a database of opioid quality improvement initiatives for doctors that can help them determine next steps for improving patient care, including referrals into chronic pain management or substance use disorder treatment programs.

Cigna is also implementing additional customer safety measures in support of the CDC guidelines. Effective July 1, most new prescriptions for a long-acting opioid that are not being used as part of treatment for cancer or sickle cell disease, or for hospice care, will be subject to prior authorization, and most new prescriptions for a short-acting opioid will be subject to quantity limits. According to the CDC, drug overdoses are the leading cause of accidental death in the United States. Of the overdose deaths that occurred in 2015, 63 percent involved an opioid.

“A a country, we have developed an overreliance on opioids to manage pain. If we’re going to break the opioid epidemic, we need to change that culture,”Cordani said. “Helping doctors become more aware of their own prescribing patterns and the effectiveness of non-narcotic alternatives for pain management is key to helping our customers have better health outcomes. For those who have become dependent on opioids, we need to treat them as compassionately as we would someone suffering from any other chronic disease and help them with recovery.”

Cigna continues to work closely with Shatterproof, a national nonprofit organization dedicated to reducing the devastation that addiction causes to families and the stigma associated with this disease. A Cigna Foundation grant helped the organization launch a comprehensive online portal earlier this year. It has the most up-to-date, evidence-based information on how to understand, prevent, intervene, treat, and recover from substance use disorders.

Liability Policy has “No Potential” Comp Coverage

Sacramento Lopez brought an action against plaintiffs Elena Delgadillo and Jesus Cortes in 2009 (the Lopez litigation), alleging he had suffered injuries in a fall from the roof of plaintiffs’ property in Hayward, where he was working as their employee.

Lopez also alleged  Delgadillo and Cortes had violated Labor Code requirements to pay overtime wages and provide meal and rest breaks. Plaintiffs Delgadillo and Cortes tendered the defense of the Lopez litigation to their business owner’s insurance carrier, United States Liability Ins. Co. (USLI), which denied plaintiffs’ claim.

Plaintiffs’ insurance policy contained the following exclusions pertinent to this case: “d. Workers’ Compensation And Similar Laws [¶] Any obligation of the insured under a workers’ compensation, disability benefits or unemployment compensation law or any similar law. [¶] e. Employer’s Liability [¶] “Bodily Injury’ to: [¶] (1) An ’employee’ of the insured arising out of and in the course of: [¶] (a) Employment by the insured; or [¶] Performing duties related to the conduct of the insured’s business[.] [¶] . . . [¶] This exclusion applies: [¶] (1) Whether the insured may be liable as an employer or in any other capacity . . .”

Plaintiffs Delgadillo and Cortes brought this action against USLI. Their causes of action for breach of contract and breach of the covenant of good faith and fair dealing were based on the theory that USLI had a contractual obligation to defend and indemnify them in the Lopez litigation. The remaining causes of action alleged in addition that USLI, through an agent, misled plaintiffs as to the coverage it would provide.

USLI demurred to the second amended complaint, primarily on the ground the policy did not cover Lopez’s claims for bodily injury or Labor Code violations.

The trial court sustained the demurrer to the Delgadillo and Cortes action against USLI without leave to amend. It took judicial notice of the verdict form for the negligence claim in the Lopez litigation, which indicated Lopez sustained his injury during the course of his employment by Delgadillo and Cortes. Because the policy explicitly excluded coverage for bodily injury sustained by an employee in the course of employment, the court ruled, plaintiffs could not state a cause of action for breach of contract against USLI.

The court of appeal affirmed the dismissal in the unpublished case of Delgadillo v. United States Liability Ins. Co..

The trial court correctly concluded the policy provided no potential for coverage, and therefore USLI had no duty to defend plaintiffs in the Lopez litigation and there was no breach of contract. Plaintiffs suggest no theory upon which their remaining causes of action for breach of the implied covenant of good faith and fair dealing, fraud, deceit, and intentional infliction of emotional distress may be maintained in the absence of a duty to defend.

Drug Makers Roll Back Prices After White House Pressure

In January, President Trump put the pharmaceutical industry on notice that drug prices were too high. He explained that drug companies were “getting away with murder.” Trump added, “PhRMA has a lot of lobbies, a lot of lobbyists, a lot of power. And there’s very little bidding on drugs. We’re the largest buyer of drugs in the world, and yet we don’t bid properly. We’re going to start bidding. We’re going to save billions of dollars over a period of time.”

Trump lamented that the pharmaceutical lobby impeded the ability for the government to negotiate drug prices. “We don’t do it,” he said. “Why? Because of the drug companies.”

In the past, Congress has failed to enact sufficient reforms to lower drug prices. When Congress was drafting the Medicare Part D prescription-drug benefit, big PhRMA added a provision which banned the Centers for Medicare and Medicaid Services from negotiating with drug companies to set prices.

Last December, the Senate blocked a measure from Senator Bernie Sanders to amend the 21st Century Cures Act, allowing the importation of prescription drugs from other countries and for Medicare to negotiate drug prices. Sanders said on the Senate floor, “I am quite confident that all of my Republican colleagues will support an amendment in my hands that will do exactly what Trump said he would accomplish as president.”

In March, Trump tweeted that he is working on a new system to bring down drug prices. Later that month, two of the biggest pharmaceutical firms announced that they will lower the cost of their pharmaceuticals.

Sanofi and Regneron Pharmaceuticals Inc. said that its new treatment for atopic dermatitis, a painful skin condition, will cost $37,000. This is a substantial decrease from the $50,000 price tag for similar treatments.

Roche Holdings AG, lowered its price for a multiple sclerosis drug to $65,000, 25 percent cheaper compared to a 15 year-old competitor, Rebif.

Regeneron CEO Leonard Schleifer told investors, “We believe that Sanofi and Regeneron and the payers are heading perhaps towards setting a new paradigm.” Schleifer added, “But it ain’t over yet.”

Roger Longman, CEO of data analytics company Real Endpoints, said that PhRMA companies will have to lower drug prices under President Trump. Longman said, “In the old days, if you could convince the physician that one drug was slightly better than another, then he or she would prescribe it, it didn’t matter what the cost was.” Longman added, “Now, the decision makers are the payers: the insurance companies, the employers.”

Marathon Pharmaceuticals paused the launch of its new drug, Emflaza, facing intense public scrutiny regarding the drug’s astronomical $89,000 price tag. Martin Shkreli, famous for raising the price of the drug Daraprim, said that, “These guys invented price increases. – literally learned it from them.”

Since the election of Donald Trump, several large drug companies offered to lower the annual increase of drug prices. Novo Nordisk President Jakob Riis promised to limit the annual increase in drug prices. Riis explained, “We hear from more and more people living with diabetes about the challenges they face affording healthcare, including the medicines we make. We take this issue seriously and have been thinking about what we can do to better support patients,” Riis said. “This has become a responsibility that needs to be shared among all those involved in healthcare and we’re going to do our part.”

Novo Nordisk followed the leadership of Brent Saunders, chief executive of Allergan, who issued a “social contract,” promising to limit the annual increase of the price of pharmaceuticals.

Merck, Johnson & Johnson, and Lilly unveiled plans to increase their transparency regarding their drug pricing.

FBI Operation Backlash Claims Another Plea Deal

Operation Backlash, has been an extensive FBI-led undercover investigation that revealed a widespread workers’ compensation kickback scheme, including attorneys, doctors and medical providers who referred patients for health services in exchange for money.

Operation Backlash was first announced in November 2015 when the initial round of federal indictments was handed down. San Diego chiropractor Steven J. Rigler and San Diego workers’ compensation attorney Sean O’Keefe previously pleaded guilty to federal charges.

“When law enforcement became aware of the scam, we began following the trail of dirty money and it took us in many different directions,” San Diego District Attorney Bonnie Dumanis said. “The circle of criminal conduct continues to widen with today’s charges, and we expect additional indictments and arrests in the future.”

As alleged in one of the indictments, Los Angeles radiologist Ronald Grusd paid bribes to a San Diego chiropractor in exchange for patient referrals. The bribes were funneled to the chiropractor via Grusd’s corporation, Willows Consulting, a shell company. The checks were labeled “professional services,” but this was allegedly a sham.

Grusd’s practice, California Imaging Network Medical Group, has clinics in San Diego, Los Angeles, Beverly Hills, Fresno, Rialto, Santa Ana, Studio City, Bakersfield, Calexico, East Los Angeles, Lancaster, Victorville and Visalia.

Trial in the case pending against Grusd was set for June 6, 2017. On March 31, 2017, Defendants Grusd, California Imaging Network Medical Group, and Willows Consulting Company rejected a plea offer in this case.

On April 7, his attorneys moved for a continuance, claiming that they did not have sufficient time to prepare his defense. Last December they say they were provided with digital discovery documents by the prosecutors which were placed on a 2 terabyte drive that can hold millions of documents and recordings. Prosecutors responded objecting to a trial continuance beyond August. No ruling has been made, thus the Grusd case remains in process with an unknown trial date.

The U.S. Attorney’s Office also announced federal indictments against additional defendants. They include patient recruiters, Fermin Iglesias, Carlos Arguello, Miguel Morales and four corporations. The corporations are Providence Scheduling, Inc., Medex Solutions, Inc., Prime Holdings International, Inc. and Meridian Medical Resources, Inc., doing business as Meridian Rehab Care.

The three federal defendants are accused of recruiting individuals to file workers’ compensation claims resulting from an on-the-job injury. The defendants then directed these patients to specific chiropractors who, in exchange for dozens of new workers’ compensation patients each month, agreed to meet a quota set by the defendants for referrals of the new patients for ancillary goods and services such as MRIs and durable medical equipment from specific providers.

According to the indictment, Providence Scheduling oversaw the scheduling of applicants recruited by defendant Arguello and others, and their assignment to a primary treating physician, which included chiropractors. Defendants Iglesias and Arguello decided which physicians were eligible to receive applicants from defendant Providence Scheduling.

Prosecutors claim the purpose of the conspiracy was to fraudulently obtain money from insurers by submitting claims for ancillary procedures and DME that were secured through a pattern of bribes and kickbacks in the form of an illegal cross-referral scheme in exchange for the referral of patients to particular providers of ancillary procedures.

Near the end of March, 2017, Providence Scheduling entered into a Plea Agreement to plead guilty. The Agreement has been filed with the federal court, but remains sealed until processed through a Magistrate Judge review and then to final disposition by the federal judge in charge of the case.

WCIRB Committee Votes to Lower Comp Rates

Citing lower medical loss and allocated loss adjustment expense development, continued acceleration in claim settlement, and recent indemnity claim frequency decreases, the insurer and public members of the WCIRB Governing Committee who were in attendance voted unanimously to authorize the WCIRB to submit a mid-year pure premium rate filing to the California Department of Insurance (CDI).

The filing will propose a July 1, 2017 average advisory pure premium rate of $2.02 per $100 of payroll which is 16.5% lower than the corresponding industry average filed pure premium rate of $2.42 as of January 1, 2017 and 7.8% less than the Insurance Commissioner’s approved average January 1, 2017 advisory pure premium rate of $2.19. The recent rate decline is therefore favorable to employers as seen on this list:

7/1/2017 Indicated Average Pure Premium Rate: $ 2.02
1/1/2017 Indicated Average Pure Premium Rate: $ 2.22
1/1/2017 Average Approved Pure Premium Rate: $2.19
1/1/2017 Industry Average Filed Pure Premium Rate: $2.42

The Governing Committee’s decision was based on the WCIRB Actuarial Committee’s analysis of insurer loss and loss adjustment experience as of December 31, 2016, which was reviewed at public meetings of the Actuarial Committee held on March 21, and April 3, 2017.

The Actuarial Committee noted that cumulative trauma claims continue to increase, particularly in the Los Angeles region. In addition, medical severities are beginning to increase after several years of more modest severity trends driven by Senate Bill No. 863.

Despite these upward pressures on system costs, the Governing Committee believed that lower frequency and favorable loss and allocated loss adjustment expense development, partially driven by increases in claim settlement rates, warranted a reduction in the industry average pure premium rate as of July 1, 2017.

The WCIRB anticipates submitting its filing to the CDI by April 14, 2017.

The filing and all related documents will be available in the Publication and Filings section of the WCIRB website and the WCIRB will issue a Wire Story once the filing has been submitted.

Documents related to the Governing Committee meeting, including the agenda and materials displayed or distributed at the meeting, are available on the Committee Documents page of the WCIRB website.

O.C. Doctor Sentenced After Faking Own Death

A medical doctor who fled the United States nearly 15 years ago and faked his own death to avoid prosecution in a healthcare fraud case was sentenced to 29 months in federal prison for fleeing justice.

Tigran Svadjian, 58, a naturalized U.S. citizen originally from Armenia who was residing in Newport Beach prior to fleeing the country in September 2002, was sentenced late this afternoon by United States District Judge Michael W. Fitzgerald.

Svadjian pleaded guilty in November to one count of unlawful flight to avoid prosecution.

In a case filed in 2002 in United States District Court in Sacramento, Svadjian, who operated medical clinics in Los Angeles and Fresno, had agreed to plead guilty in a $2.4 million scheme to defraud Medi-Cal by submitting bills for tests that had not been performed, in many cases because the “patients” were dead. After being ordered to appear in federal court in the Eastern District of California for an arraignment in that case, he fled to Russia, leaving behind his wife and son.

On October 24, 2002, the United States Embassy in Moscow received notification that Svadjian had died of pneumonia and that his body had been cremated. Relying on this false information, the Embassy then issued a report documenting the death, and Svadjian’s defense counsel submitted that report to federal prosecutors.

When he pleaded guilty, Svadjian admitted that he paid a Russian police officer in 2002 to submit an official report about his death to the United States Embassy. Soon after, Svadjian obtained a fraudulent Russian passport in a different name and relocated to Hurghada, Egypt, where he occasionally worked as a scuba instructor.

In January 2013, after lengthy and unsuccessful attempts to locate Svadjian or to obtain further confirmation of his death, prosecutors in the Eastern District of California dismissed the healthcare fraud case.

Svadjian was taken into custody by Egyptian authorities on August 1 – nearly 14 years after he fled the United States. Svadjian had been deported to Egypt by Ukrainian authorities after they determined he was travelling on a fraudulent Lithuanian passport. Egyptian authorities discovered in his residence an old United States passport with his true name.

Svadjian “did not simply flee from prosecution,” prosecutors wrote in a sentencing memorandum filed with the court. “Instead, defendant planned and implemented a sophisticated, fraudulent scheme that involved bribing foreign officials, using false statements to mislead U.S. State Department officials into creating a false death certificate, and submitting that false certificate to federal prosecutors. Defendant then hid from U.S. authorities through the use of false identities for approximately 15 years. He abandoned his wife, son, and parents, and started a whole new life without them because he did not want to spend time in prison.”